Shenzhen Chipscreen Biosciences Co., Ltd., established in March 2001 by a group of senior scientists returned from the United States, is a pioneer in drug innovation and development in China. With a comprehensive vision in emphasizing innovation, safety and quality, Chipscreen Biosciences focuses on developing innovative drugs with new mechanisms of action (MOA) for the treatment of human diseases in five major therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders and antivirals, so as to provide patients with affordable, efficacious drugs to meet their clinical needs. Chipscreen Biosciences was the first biotech company approved for listing on the SSE STAR Market (stock code: 688321.SH).
Over the past 21 years, Chipscreen Biosciences has perfected a core technology platform for innovative drug discovery (a.k.a. integrated drug discovery and early evaluation platform based on chemical genomics) that has greatly improved the efficiency of clinical drug development, shortening the development time and reducing failure rates. On the back of this core technology, Chipscreen Biosciences has successfully developed a series of national class I drugs featuring new molecular entities and MOA, including the anti-tumor epigenetic regulator Chidamide, the new-generation insulin sensitizer Chiglitazar for the treatment of type 2 diabetes, the triple-pathway targeted kinase inhibitor Chiauranib, and the autoimmune disorder inhibitor CS12192. An additional 20 projects covering multiple therapeutic areas are at varying stages in the development pipeline, from early drug discovery to preclinical research. Notably, Chidamide, as the first product of Chipscreen approved by China in 2014, is the first original innovative drug in the history of the Chinese pharmaceutical industry, and also China’s first new drug patented in developed countries for global development.
Thanks to innovative research driven by core technology and sustainable development founded on a rich and diversified product line, Chipscreen has evolved into a modern biotech firm integrating early research, clinical development, product development and GMP production, pharmaceutical regulation and pharmacovigilance, marketing, commercial and market access, and intellectual property rights. With over 1,000 employees, 29% of whom are R&D personnel and 5% of whom have a doctoral degree, Chipscreen Biosciences can draw on a host of nationally-leading and top-level talent. Meanwhile, as a national high-tech enterprise and one of the first national “innovative drug incubation bases”, Chipscreen Biosciences has independently undertaken a number of key national science and technology and drug innovation projects as part of major national initiatives such as the 863 State High-Tech Development Program and the 10th to 13th Five-Year Plans. As of the end of June 2022, the Group had filed more than 400 domestic and foreign invention patents, among which more than 100 have now been granted.
Guided by China’s global development strategy for boosting early R&D, Chipscreen Biosciences is actively pushing its original products to compete in highly regulated international pharmaceutical markets, as it pursues the lofty goal of leading the development of smart manufacturing of innovative drugs and innovative medical technology in China.
Shenzhen Chipscreen Pharmaceutical Ltd.
Shenzhen Chipscreen Pharmaceutical Ltd., incorporated on Mar. 16, 2017, is located at No. 21, Jinxiu East Road, Kengzi Street, Pingshan New District, Shenzhen. A wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd., it was formerly the Pingshan manufacturing base of Chipscreen Biosciences, and is now the industrialization base for the Company’s first original anti-tumor drug, Chidamide. The subsidiary consists of the Group’s innovative drug CMC technology transfer center, an oncologic API and formulation workshop, a quality management center, and other production-related supporting facilities.
Chengdu Chipscreen Pharmaceutical Ltd.
Chengdu Chipscreen Pharmaceutical Ltd., incorporated on Apr. 28, 2014, is a wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. Consisting of two sites, the Innovative Drug Manufacturing Base and the Innovative Drug R&D Center and Regional Headquarters, Chengdu Chipscreen Pharmaceutical plays a pivotal role in the regional development of the Group.
The Innovative Drug Manufacturing：Base is located at No. 298, Kangqiang Yi Road, West High-tech Zone, Chengdu. The facilities here include oncology and non-oncology API and oral solid formulation workshops, which are designed in accordance with GMP standards of the US, EU and China. In order to fully meet demand for pilot scale testing of innovative drugs, preparation of clinical samples and production of commercial batches, new facilities including workshops for oncologic and non-oncologic injections and antibody drugs are under construction.
The Innovative Drug R&D Center and Regional Headquarters：is located at No. 18, Xintongnan Yi Road, Xinchuan Science and Technology Park, South High-tech Zone, Chengdu. A vital part of the Group’s R&D system, the Innovative Drug R&D Center will work with and complement the Early Research & Development Center (Shenzhen) in building product pipelines and supporting clinical research needed for the company’s sustainable development.
Chipscreen Biosciences (United States) Limited
Chipscreen Biosciences (United States) Limited was incorporated in Oct. 16, 2020. Registered in Newark, Delaware but with its offices located at Somerset, New Jersey, Chipscreen Biosciences (United States) Limited is a wholly-owned subsidiary of Shenzhen Chipscreen Biotechnology Co., Ltd. that serves as the international clinical development and market expansion center of the Company, assisting with Chipscreen’s globalization.